ATHE
Alterity Therapeutics LimitedNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.69
P/S
25.54
EV/EBITDA
-2.43
DCF Value
$-14.68
FCF Yield
-2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.8%
Operating Margin
-525.6%
Net Margin
-380.7%
ROE
-30.2%
ROA
-25.6%
ROIC
-31.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $-9.4M | $-0.54 |
| Q4 2025 | $3.8M | $-5.0M | $-0.42 |
| FY 2025 | $5.4M | $-12.1M | $-1.14 |
| Q2 2025 | $1.6M | $-7.2M | $-0.84 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Company Info
Sector
Healthcare
Industry
—
Country
AU
Exchange
NASDAQ
Beta
-0.07
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.